Trade BioLife Solutions, Inc. - BLFS CFD
Market information is presented
as of 2023-09-21
- Summary
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
BioLife Solutions Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 14.63 |
Open* | 14.33 |
1-Year Change* | -1.31% |
Day's Range* | 14.33 - 14.67 |
52 wk Range | 10.48-26.96 |
Average Volume (10 days) | 554.24K |
Average Volume (3 months) | 9.01M |
Market Cap | 565.37M |
P/E Ratio | -100.00K |
Shares Outstanding | 43.49M |
Revenue | 162.22M |
EPS | -1.96 |
Dividend (Yield %) | N/A |
Beta | 1.64 |
Next Earnings Date | Nov 7, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 14.53 | 0.15 | 1.04% | 14.38 | 14.69 | 14.23 |
Jun 28, 2022 | 14.63 | -0.35 | -2.34% | 14.98 | 15.46 | 14.42 |
Jun 27, 2022 | 14.88 | -0.81 | -5.16% | 15.69 | 15.75 | 14.38 |
Jun 24, 2022 | 15.68 | 0.08 | 0.51% | 15.60 | 16.45 | 15.49 |
Jun 23, 2022 | 15.67 | 1.26 | 8.74% | 14.41 | 15.72 | 14.41 |
Jun 22, 2022 | 14.45 | 1.06 | 7.92% | 13.39 | 14.81 | 13.39 |
Jun 21, 2022 | 13.80 | -0.14 | -1.00% | 13.94 | 14.63 | 13.76 |
Jun 17, 2022 | 13.74 | 0.39 | 2.92% | 13.35 | 14.30 | 13.24 |
Jun 16, 2022 | 13.24 | -0.11 | -0.82% | 13.35 | 13.66 | 13.07 |
Jun 15, 2022 | 14.08 | 1.10 | 8.47% | 12.98 | 14.23 | 12.97 |
Jun 14, 2022 | 12.95 | -0.17 | -1.30% | 13.12 | 13.19 | 12.57 |
Jun 13, 2022 | 13.07 | -0.17 | -1.28% | 13.24 | 13.66 | 13.01 |
Jun 10, 2022 | 14.07 | 0.13 | 0.93% | 13.94 | 14.24 | 13.78 |
Jun 9, 2022 | 14.37 | 0.39 | 2.79% | 13.98 | 14.52 | 13.98 |
Jun 8, 2022 | 14.45 | -0.03 | -0.21% | 14.48 | 15.15 | 14.30 |
Jun 7, 2022 | 14.69 | 1.21 | 8.98% | 13.48 | 14.72 | 13.48 |
Jun 6, 2022 | 13.90 | 0.17 | 1.24% | 13.73 | 14.40 | 13.57 |
Jun 3, 2022 | 13.73 | -0.24 | -1.72% | 13.97 | 14.02 | 13.48 |
Jun 2, 2022 | 14.14 | 1.01 | 7.69% | 13.13 | 14.36 | 13.13 |
Jun 1, 2022 | 13.32 | -0.44 | -3.20% | 13.76 | 14.16 | 13.32 |
BioLife Solutions, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, November 7, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 BioLife Solutions Inc Earnings Release Q3 2023 BioLife Solutions Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 161.759 | 119.156 | 48.087 | 27.371 | 19.742 |
Revenue | 161.759 | 119.156 | 48.087 | 27.371 | 19.742 |
Cost of Revenue, Total | 107.937 | 82.108 | 20.646 | 8.76 | 6.217 |
Gross Profit | 53.822 | 37.048 | 27.441 | 18.611 | 13.525 |
Total Operating Expense | 307.3 | 147.865 | 54.328 | 17.483 | 16.08 |
Selling/General/Admin. Expenses, Total | 69.24 | 47.674 | 21.686 | 13.594 | 8.565 |
Research & Development | 14.798 | 11.821 | 6.72 | 3.168 | 1.298 |
Operating Income | -145.541 | -28.709 | -6.241 | 9.888 | 3.662 |
Interest Income (Expense), Net Non-Operating | 0.01 | -0.485 | 1.359 | -0.238 | -0.396 |
Gain (Loss) on Sale of Assets | |||||
Other, Net | 0.704 | 0.168 | 3.601 | -12.848 | -28.271 |
Net Income Before Taxes | -144.827 | -29.026 | -1.281 | -3.198 | -25.005 |
Net Income After Taxes | -139.805 | -8.908 | 1.983 | -1.657 | -25.005 |
Minority Interest | |||||
Net Income Before Extra. Items | -139.805 | -8.908 | 1.983 | -1.657 | -25.005 |
Net Income | -139.805 | -8.908 | 1.983 | -1.657 | -25.005 |
Income Available to Common Excl. Extra. Items | -139.805 | -8.908 | 1.822 | -1.657 | -25.344 |
Income Available to Common Incl. Extra. Items | -139.805 | -8.908 | 1.822 | -1.657 | -25.344 |
Diluted Net Income | -139.805 | -8.908 | 1.822 | -1.657 | -25.344 |
Diluted Weighted Average Shares | 42.481 | 38.5039 | 27.3063 | 19.4603 | 16.2565 |
Diluted EPS Excluding Extraordinary Items | -3.291 | -0.23135 | 0.06672 | -0.08515 | -1.55901 |
Diluted Normalized EPS | -1.5916 | -0.31508 | 0.08696 | -0.39137 | -1.55901 |
Total Adjustments to Net Income | 0 | 0 | -0.161 | 0 | -0.339 |
Depreciation / Amortization | 9.697 | 8.202 | 3.033 | 1.079 | 0 |
Unusual Expense (Income) | 110.382 | -4.815 | 0.668 | -9.168 | 0 |
Other Operating Expenses, Total | -4.754 | 2.875 | 1.575 | 0.05 | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 39.508 | 37.703 | 44.259 | 40.747 | 40.533 |
Revenue | 39.508 | 37.703 | 44.259 | 40.747 | 40.533 |
Cost of Revenue, Total | 27.696 | 23.664 | 30.288 | 27.009 | 26.194 |
Gross Profit | 11.812 | 14.039 | 13.971 | 13.738 | 14.339 |
Total Operating Expense | 49.673 | 51.308 | 94.5 | 52.152 | 117.096 |
Selling/General/Admin. Expenses, Total | 21.72 | 21.313 | 19.529 | 16.858 | 17.067 |
Research & Development | 4.84 | 4.152 | 4.164 | 3.425 | 3.428 |
Depreciation / Amortization | 1.45 | 1.459 | 1.461 | 2.513 | 2.863 |
Unusual Expense (Income) | -5.115 | 0 | 40.464 | 0.001 | 69.905 |
Other Operating Expenses, Total | -0.918 | 0.72 | -1.406 | 2.346 | -2.361 |
Operating Income | -10.165 | -13.605 | -50.241 | -11.405 | -76.563 |
Interest Income (Expense), Net Non-Operating | -0.419 | -0.411 | -0.506 | 0.707 | -0.032 |
Other, Net | 0.39 | 0.394 | 0.434 | 0.142 | -0.022 |
Net Income Before Taxes | -10.194 | -13.622 | -50.313 | -10.556 | -76.617 |
Net Income After Taxes | -10.199 | -13.714 | -50.228 | -9.957 | -72.878 |
Net Income Before Extra. Items | -10.199 | -13.714 | -50.228 | -9.957 | -72.878 |
Net Income | -10.199 | -13.714 | -50.228 | -9.957 | -72.878 |
Income Available to Common Excl. Extra. Items | -10.199 | -13.714 | -50.228 | -9.957 | -72.878 |
Income Available to Common Incl. Extra. Items | -10.199 | -13.714 | -50.228 | -9.957 | -72.878 |
Diluted Net Income | -10.199 | -13.714 | -50.228 | -9.957 | -72.878 |
Diluted Weighted Average Shares | 43.4412 | 43.0276 | 42.7949 | 42.648 | 42.4602 |
Diluted EPS Excluding Extraordinary Items | -0.23478 | -0.31873 | -1.17369 | -0.23347 | -1.71638 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.31131 | -0.31873 | -0.55909 | -0.23345 | -0.64625 |
Total Adjustments to Net Income | 0 | 0 | |||
Dilution Adjustment |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 138.452 | 126.088 | 114.712 | 24.113 | 37.564 |
Cash and Short Term Investments | 19.442 | 69.86 | 90.403 | 6.448 | 30.657 |
Cash & Equivalents | 19.442 | 69.86 | 90.403 | 6.448 | 30.657 |
Short Term Investments | |||||
Total Receivables, Net | 33.936 | 23.217 | 8.006 | 5.345 | 3.045 |
Accounts Receivable - Trade, Net | 33.936 | 23.217 | 8.006 | 5.345 | 3.045 |
Total Inventory | 34.904 | 28.345 | 11.602 | 10.972 | 3.509 |
Prepaid Expenses | 6.879 | 4.656 | 4.648 | 1.348 | 0.353 |
Total Assets | 450.229 | 554.286 | 234.829 | 92.816 | 45.467 |
Property/Plant/Equipment, Total - Net | 48.266 | 46.611 | 24.517 | 10.534 | 1.319 |
Property/Plant/Equipment, Total - Gross | 62.389 | 55.624 | 28.77 | 13.229 | 3.647 |
Accumulated Depreciation, Total | -14.123 | -9.013 | -4.253 | -2.695 | -2.328 |
Intangibles, Net | 32.088 | 152.149 | 31.049 | 21.982 | 0 |
Long Term Investments | 5.069 | 4.372 | 5.872 | 2.5 | 6.548 |
Other Long Term Assets, Total | 1.613 | 0.325 | 0.23 | 0.05 | 0.036 |
Total Current Liabilities | 44.582 | 42.7 | 15.573 | 7.669 | 1.939 |
Accounts Payable | 15.367 | 14.945 | 3.672 | 3.119 | 0.72 |
Accrued Expenses | 16.245 | 11.405 | 4.931 | 4.173 | 1.089 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 10.998 | 15.339 | 6.348 | 0.377 | 0.13 |
Total Liabilities | 86.041 | 76.239 | 29.583 | 49.362 | 30.835 |
Total Long Term Debt | 23.919 | 6.644 | 0.667 | 0 | 0 |
Long Term Debt | 23.793 | 6.353 | 0.655 | ||
Minority Interest | |||||
Other Liabilities, Total | 17.29 | 21.408 | 13.343 | 41.693 | 28.896 |
Total Equity | 364.188 | 478.047 | 205.246 | 43.454 | 14.632 |
Common Stock | 0.043 | 0.042 | 0.033 | 0.021 | 0.019 |
Additional Paid-In Capital | 611.739 | 585.397 | 302.598 | 143.485 | 113.008 |
Retained Earnings (Accumulated Deficit) | -246.915 | -107.11 | -97.385 | -100.052 | -98.395 |
Other Equity, Total | -0.679 | -0.282 | |||
Total Liabilities & Shareholders’ Equity | 450.229 | 554.286 | 234.829 | 92.816 | 45.467 |
Total Common Shares Outstanding | 42.8322 | 41.8175 | 33.0392 | 20.8255 | 18.5474 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Goodwill, Net | 224.741 | 224.741 | 58.449 | 33.637 | 0 |
Other Current Assets, Total | 43.291 | 0.01 | 0.053 | ||
Current Port. of LT Debt/Capital Leases | 1.972 | 1.011 | 0.622 | ||
Capital Lease Obligations | 0.126 | 0.291 | 0.012 | ||
Deferred Income Tax | 0.25 | 5.487 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 132.789 | 138.452 | 135.874 | 118.057 | 118.701 |
Cash and Short Term Investments | 19.105 | 19.442 | 27.036 | 24.001 | 59.463 |
Cash & Equivalents | 19.105 | 19.442 | 27.036 | 24.001 | 59.463 |
Total Receivables, Net | 30.343 | 33.936 | 32.436 | 31.257 | 24.271 |
Accounts Receivable - Trade, Net | 30.343 | 33.936 | 32.436 | 31.257 | 24.271 |
Total Inventory | 41.329 | 34.904 | 33.747 | 33.335 | 30.2 |
Prepaid Expenses | 6.201 | 6.879 | 8.041 | 6.89 | 4.757 |
Other Current Assets, Total | 35.811 | 43.291 | 34.614 | 22.574 | 0.01 |
Total Assets | 446.47 | 450.229 | 487.679 | 470.379 | 544.012 |
Property/Plant/Equipment, Total - Net | 50.939 | 48.266 | 47.236 | 45.873 | 46.647 |
Property/Plant/Equipment, Total - Gross | 66.013 | 62.389 | 60.495 | 57.457 | 56.851 |
Accumulated Depreciation, Total | -15.074 | -14.123 | -13.259 | -11.584 | -10.204 |
Goodwill, Net | 224.741 | 224.741 | 224.741 | 224.741 | 224.741 |
Intangibles, Net | 30.629 | 32.088 | 74.013 | 76.524 | 149.286 |
Long Term Investments | 5.069 | 5.069 | 5.069 | 4.372 | 4.372 |
Other Long Term Assets, Total | 2.303 | 1.613 | 0.746 | 0.812 | 0.265 |
Total Current Liabilities | 47.319 | 44.582 | 36.948 | 33.298 | 35.04 |
Accounts Payable | 15.525 | 15.367 | 13.14 | 11.537 | 11.711 |
Accrued Expenses | 17.77 | 16.245 | 10.118 | 9.489 | 8.866 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.411 | 1.972 | 2.223 | 1.516 | 0.708 |
Other Current Liabilities, Total | 12.613 | 10.998 | 11.467 | 10.756 | 13.755 |
Total Liabilities | 88.363 | 86.041 | 79.43 | 58.066 | 65.492 |
Total Long Term Debt | 23.787 | 23.919 | 24.373 | 6.401 | 6.566 |
Long Term Debt | 23.692 | 23.793 | 24.207 | 6.188 | 6.313 |
Capital Lease Obligations | 0.095 | 0.126 | 0.166 | 0.213 | 0.253 |
Other Liabilities, Total | 16.994 | 17.29 | 17.72 | 17.218 | 18.998 |
Total Equity | 358.107 | 364.188 | 408.249 | 412.313 | 478.52 |
Common Stock | 0.043 | 0.043 | 0.043 | 0.043 | 0.042 |
Additional Paid-In Capital | 619.227 | 611.739 | 604.06 | 597.81 | 591.002 |
Retained Earnings (Accumulated Deficit) | -260.629 | -246.915 | -194.597 | -184.64 | -112.086 |
Total Liabilities & Shareholders’ Equity | 446.47 | 450.229 | 487.679 | 470.379 | 544.012 |
Total Common Shares Outstanding | 43.29 | 42.8322 | 42.706 | 42.5367 | 42.3311 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 0.263 | 0.25 | 0.389 | 1.149 | 4.888 |
Other Equity, Total | -0.534 | -0.679 | -1.257 | -0.9 | -0.438 |
Preferred Stock - Non Redeemable, Net | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -139.805 | -8.908 | 1.983 | -1.657 | 3.266 |
Cash From Operating Activities | -8.488 | -4.593 | 6.645 | 1.213 | 2.348 |
Cash From Operating Activities | 6.775 | 4.663 | 2.035 | 0.718 | 0.338 |
Non-Cash Items | 134.988 | 13.835 | 3.988 | 7.086 | 2.064 |
Changes in Working Capital | -14.905 | -2.258 | -1.097 | -4.472 | -3.32 |
Cash From Investing Activities | -58.117 | -13.192 | -24.715 | -27.018 | -6.5 |
Capital Expenditures | -13.921 | -14.756 | -7.808 | -2.33 | -0.5 |
Other Investing Cash Flow Items, Total | -44.196 | 1.564 | -16.907 | -24.688 | -6 |
Cash From Financing Activities | 16.316 | -2.778 | 102.078 | 1.596 | 28.146 |
Financing Cash Flow Items | -1.843 | -1.302 | -0.499 | 0.415 | 15.707 |
Issuance (Retirement) of Stock, Net | 0.323 | 1.418 | 101.593 | 1.181 | 12.9 |
Issuance (Retirement) of Debt, Net | 17.836 | -2.894 | 0.984 | -0.025 | |
Net Change in Cash | -50.397 | -20.586 | 84.008 | -24.209 | 23.994 |
Total Cash Dividends Paid | 0 | -0.436 | |||
Amortization | 9.697 | 8.202 | 3.033 | 1.079 | |
Deferred Taxes | -5.238 | -20.127 | -3.297 | -1.541 | |
Foreign Exchange Effects | -0.108 | -0.023 | 0 | ||
Cash Interest Paid | 0.586 | 0.452 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.714 | -139.805 | -89.577 | -79.62 | -7.066 |
Cash From Operating Activities | -2.712 | -8.488 | -16.345 | -17.841 | -7.924 |
Cash From Operating Activities | 1.721 | 6.775 | 5.056 | 3.257 | 1.653 |
Amortization | 1.459 | 9.697 | 8.236 | 5.725 | 2.863 |
Non-Cash Items | 8.36 | 134.988 | 85.276 | 76.856 | 2.493 |
Changes in Working Capital | -0.551 | -14.905 | -20.399 | -19.721 | -7.268 |
Cash From Investing Activities | 2.926 | -58.117 | -43.223 | -27.34 | -2.27 |
Capital Expenditures | -4.296 | -13.921 | -8.206 | -4.265 | -2.27 |
Other Investing Cash Flow Items, Total | 7.222 | -44.196 | -35.017 | -23.075 | 0 |
Cash From Financing Activities | -0.562 | 16.316 | 16.941 | -0.47 | -0.181 |
Financing Cash Flow Items | -0.56 | -1.843 | -1.246 | -0.524 | -0.313 |
Issuance (Retirement) of Stock, Net | 0.125 | 0.323 | 0.307 | 0.301 | 0.257 |
Issuance (Retirement) of Debt, Net | -0.127 | 17.836 | 17.88 | -0.247 | -0.125 |
Net Change in Cash | -0.337 | -50.397 | -42.803 | -45.841 | -10.397 |
Deferred Taxes | 0.013 | -5.238 | -4.937 | -4.338 | -0.599 |
Foreign Exchange Effects | 0.011 | -0.108 | -0.176 | -0.19 | -0.022 |
Cash Interest Paid | 0.497 | 0.586 | 0.23 | 0.121 | 0.091 |
BioLife Solutions, Inc. Company profile
About BioLife Solutions Inc
BioLife Solutions, Inc. is engaged in developing, manufacturing, and marketing bioproduction tools and services to the cell and gene therapy (CGT) industry. Its products are used in basic and applied research, and commercial manufacturing of biologic-based therapies. The customers use its products to maintain the health and function of biologic material during sourcing, manufacturing, storage, and distribution of cells and tissues. It has a portfolio of tools and services that focus on biopreservation, frozen storage, and thawing of biologic materials. Its product offerings under bioproduction tools and services include Biopreservation media, Automated thawing devices, Cloud connected smart shipping containers, Freezer and storage technology and related components, and Biological and pharmaceutical material storage. Its Biopreservation media products consists of HypoThermosol FRS and CryoStor. Its Astero ThawSTAR product line includes automated vial and cryobag thawing products.
Financial summary
BRIEF: For the twelve months ended 31 December 2021, BioLife Solutions Inc revenues increased from $35.9M to $119.2M. Net loss decreased 57% to $8.4M. Revenues reflect Product revenue increase from $32.8M to $101.9M, Service revenue increase from $1.8M to $9.8M, Rental revenue increase from $1.4M to $7.4M. Lower net loss reflects Change in fair value of warrant liab. decrease of 99% to $121K (expense).
Equity composition
Common Stock $.001 Par, 02/11, 100M auth., 69,679,854 issd. Insiders control 70.67%. IPO 11/89, 1M units (5 Common + 5 Class A Warrants) at $5/unit by D.H. Blair & Co. Preferred Stock $.001 Par, 12,080 auth., 12,055 issd. 6/00, *9/02, Name changed from Cryomedical Sciences, Inc. 01/14, 1-for-14 Reverse stock split.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
Suite 310
3303 Monte Villa Parkway
BOTHELL
WASHINGTON 98021
US
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com